Sometimes our readers must wonder what is Wall Street thinking about when you look at the drastic fall in VITA's stock pricing since the ridiculous government backed study on Vertebroplasty was published. TSB sees this company picking up serious momentum with Cortoss as it continues to educate surgeons and patients on the long-term efficacy of the material. TSB must congratulate Koblish and his team for sticking to their strategy of being a bio-materials company and not being tempted into the hardware market. Remember the Osteotech fiasco! If anything TSB can see this organization evaluating potential opportunities for acquiring additional complimentary biomaterials to further enhance their position as a biomaterials leader in orthopaedics and spine.
Congratulations on a job well done!!!!!!